6th Biosimilars Conference 2017,

Innovations & Developments : A Decade at a Glance

3 Mar - 4 Mar 2017 China

 

2 days of informative, scientific and business development presentations, workshops, 1

to 1 meetings , speed networking sessions and interactive corporate exhibition.

Over 50 attendees representing leading pharmaceutical organisations and global biotechnology companiesand internationally renowned academic institutions

15 presentations, case studies, workshops and panel discussions focused on the key issues in follow-on biologics development and corporate business strategy 

Topics:

  • Corporate Commercial Strategy and Business Development
  • Manufacturing Biosimilars and Biobetters
  • Patent and Legal Issues in the Development of Biosimilars
  • Future Biosimilar Market, Ecomonic Models , Financial Analysis and Big Data in Pharma

20 pre-scheduled one to one meetings, exhibition and informal networking opportunities

According to market research report, 'PharmaSphere: Global Biosimilars Strategy - Regulatory Landscape, Key Drivers, Markets and Trends in 2013' published by GlobalData, the global biosimilars market is expected to be worth $168 billion by 2017. 

The growing dependence on biologics to provide significant benefits in the effective treatment of chronic diseases such as rheumatoid arthritis, psoriasis, cancer, Crohn's Disease and similar conditions has resulted in the continued increase in sales, generating over $128 billion in 2012 alone. This trend is expected to continue in the short term, growing by a Compound Annual Growth Rate (CAGR) of about 5.6% to reach over $168 billion by 2017. Afterwards, patent expirations and the existence of clearer regulatory frameworks for biosimilars will result in an upsurge of biosimilars in key biologics markets such as the US, having an adverse effect on global branded biologic sales. - See more at: http://www.transworldnews.com/1600775/global-biosimilars-market-168-billion-industry-by-2017#sthash.vAAXD4hh.dpuf

Currently, the biosimilars market is highly fragmented and its huge opportunities are attracting new players.  Asia's early commercialization and high absorption rate of the biosimilars products made it the dominant market in 2008 with 34.1% share of the global sector market. The American market (including North America and Latin America) is expected to account for nearly 35.3% of the total revenues in 2014. The European market is also gaining momentum after the approval of its first biosimilars Omnitrope in 2006. 

Sandoz has emerged as the market leader in the global market and is likely to maintain this leadership position in the coming years. Sandoz entered the biosimilars market in 2006, with the launch of Omnitrope (human growth hormone)-a biosimilar drug-in the European market. 

Teva, another major player, has the capability to provide a stiff competition to Sandoz In 2000, Teva entered the biosimilars market by setting up a clear long term biosimilar strategy.

Other notable players are Hospira (U.S.), Dr. Reddy’s Laboratories (India), Biocon Ltd. (India), Mylan (U.S.), Biopartners (Switzerland), Amgen (U.S.), and Intas Biopharmaceultical Ltd. (India).

 

Dear Industry Colleagues,

Appel Consulting Ltd Reserves the Right not to publish the names of speakers for the congress.

For further information on the congress please email Mr Rosario Critelli.

Please email rosario.critelli@appelconsulting.co.uk

Please note that this event is private.

Dear Industry Colleagues,

Appel Consulting Ltd Reserves the Right not to publish the names of speakers for the congress.

For further information on the congress please email Mr Rosario Critelli.

Please email rosario.critelli@appelconsulting.co.uk

Please note that this event is private.

Dear Industry Colleagues,

Appel Consulting Ltd Reserves the Right not to publish the names of speakers for the congress.

For further information on the congress please email Mr Rosario Critelli.

Please email rosario.critelli@appelconsulting.co.uk

Please note that this event is private.

Dear Industry Colleagues,

Appel Consulting Ltd Reserves the Right not to publish the names of workshop leaders for the congress.

For further information on the congress please email Mr Rosario Critelli.

Please email rosario.critelli@appelconsulting.co.uk

Please note that this event is private.

PLATINUM SPONSORS 2015 BIOMARKERS

 

http://www.siliconbiosystems.com/

Media Partners

PharmaVOICE magazine provides commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 25,000 BPA-qualified subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.

SelectScience.net is the leading online product and application publication for laboratory scientists featuring the latest news, application articles, videos, product directory and product reviews. Membership is fast, free and provides access to all of the SelectScience services. SelectScience.tv is a unique video news channel for laboratory application and product information.

 

 

PharmiWeb.com is the leading jobs and news portal for the pharmaceutical, biotech and life sciences sector. Constantly updated with the latest events, features, news and thousands of jobs from all the leading employers in the sector. PharmiWeb.com is brought to you by innovative online publisher and e-business solutions provider, PharmiWeb Solutions.

 

Genetic Engineering & Biotechnology News (GEN)  is the most authoritative and widely read biotechnology news publication in the world.  Published 21 times a year, GEN's unique news and technology content  focus includes  the entire  bioproduct life cycle from early-stage R&D to applied  research and bioprocess through to commercialization. GENis  the only publication that  provides  the full  range of the biotechnology market coverage  in areas such as omics, drug and biomarker discovery, bioprocessing, clinical research, molecular diagnostics, and biobusiness.  For a free subscription, go to http://www.genengnews.com/subscriptions.aspx

 

 

Life sciences business intelligence firm Cutting Edge Information offers customized consulting and a growing library of targeted and insightful primary/secondary research reports that its competition cannot. Executives at more than 400 pharmaceutical and biotech firms have used Cutting Edge Information’s comprehensive, original pharmaceutical and benchmarking data and consulting services to make critical decisions on issues of both strategy and tactics.

 

GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.

The Crown Plaza London City Hotel 
19 New Bridge Street 
London 
EC4V 6DB

http://www.ihg.com/crowneplaza/hotels/us/en/london/loncy/hoteldetail?cm_mmc=GoogleMaps-_-cp-_-GBEN-_-loncy

Biomarkers 2015 Conference Feedback

Huw Ricketts, EMEA Regional Account Manager-Pharma, NanoString Technologies Inc.

“ The venue and catering were excellent” “ Great speakers”

Farideh Bischoff, Executive Director, Silicon Biosystem

“The subject matter was of high interest” “ The speakers were great”

Jan Voskuil, Chief Scientific Officer, Everest Biotech

“Good experience with excellent contributions”

Richard Holman, Laboratory Manager, Fisher BioService

“The meeting was very informative and interesting” “ Very good venue and facilities”